SEC Form 4 · accession 0001197350-26-000008
Mirum Pharmaceuticals, Inc. · MIRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — CHIEF FINANCIAL OFFICER
Period of report
Jul 6, 2026
Accepted (ET)
Jul 8, 2026 · 5:07 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001759425
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 6, 2026 | S | 3,124 | $121.67 | D | 44,057 | D | |
| Common StockF3 | Jul 6, 2026 | S | 1,048 | $122.43 | D | 43,009 | D | |
| Common StockF4 | Jul 6, 2026 | S | 528 | $123.84 | D | 42,481 | D | |
| Common Stock | Jul 6, 2026 | S | 300 | $124.94 | D | 42,181 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.
- F2. The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3. The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4. The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.